Mutated ZFHX3 is associated with favorable overall survival in non-small cell lung cancer patients who received immune checkpoint inhibitor treatments, and ZFHX3 mutations are also positively correlated with known immunotherapy response biomarkers like neoantigen load, T cell infiltration, and higher tumor mutation load [54]. The gene discussed is ZFHX3; the disease is neoplasm.